Investor Presentation Full Year 2017
Investor Presentation
Full year 2017
Slide 26
Novo Nordisk has leading positions in diabetes,
haemophilia and obesity
Diabetes
Obesity
DKK
billion
Market value
DKK
Market value
DKK
Haemophilia
Market value
Novo Nordisk value market share
billion
Novo Nordisk value market share
billion
Global market position
Global market position
Novo Nordisk value market share
Global market position
500
400
#1
50%
10
#1
50%
#2
70
50%
60
40%
00
8
40%
40%
50
300
30%
6
30%
30%
40
200
CAGR¹ value: 16.2%
- 20%
4
CAGR² value: 46.6%
- 20%
30
CAGR¹ value: 1.7%
20%
20
100
10%
2
- 10%
10%
10
0%
0%
0%
Nov
2012
Nov
2017
Dec
2015
Nov
2017
FY
2012
FY
2016
1 CAGR for 5-year period
Source: IQVIA (formerly IMS) MAT Nov, 2017 value figures
changing
Note: Value data is based on Australia, Belgium, Brazil, Canada,
Chile, Denmark, Germany, Italy, Mexico, Russia, Spain, UAE, USA
2 CAGR for 2-year period
Source: IQVIA (formerly IMS) MAT Nov, 2017 value figures
Note: Annual sales figures for Haemophilia A, B and
inhibitor segment
Source: Company reports
diabetes®
novo nordiskView entire presentation